MAPT and Alzheimer disease: CSF levels of Aβ42 and tau protein are currently the only reliable biomarkers for the diagnosis of AD, with sufficient sensitivity and specificity [52], while efforts to establish less invasive blood-derived biomarkers have been hitherto unsuccessful.